Richmond News Now

Atrial Fibrillation Market is Projected to Grow During the Forecast Period (2022-32) – Estimates DelveInsight | Key Companies – Bayer, Allergan, Anthos Therapeutics, Omeicos, InCarda Therapeutics

 Breaking News
  • No posts were found

Atrial Fibrillation Market is Projected to Grow During the Forecast Period (2022-32) – Estimates DelveInsight | Key Companies – Bayer, Allergan, Anthos Therapeutics, Omeicos, InCarda Therapeutics

November 08
17:48 2022
Atrial Fibrillation Market is Projected to Grow During the Forecast Period (2022-32) - Estimates DelveInsight | Key Companies - Bayer, Allergan, Anthos Therapeutics, Omeicos, InCarda Therapeutics
Delveinsight Business Research LLP
As per DelveInsight, the market size of Atrial Fibrillation is anticipated to increase in the upcoming years owing to the rise in the prevalent cases of Atrial Fibrillation in 7MM. At present, Entasis Therapeutics, Qpex Biopharma, Vaxdyn, Omnix Medical, Aridis Pharmaceuticals, and several others are actively working towards the development of potential therapy to overcome the unmet medical needs of the currently used therapeutics in the Atrial Fibrillation Market.

DelveInsight’s “Atrial Fibrillation Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Atrial Fibrillation market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Atrial Fibrillation market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Atrial Fibrillation Market

Atrial Fibrillation: An Overview

Atrial Fibrillation (AF) is an abnormal heart rhythm (arrhythmia) characterized by the rapid and irregular beating of the heart’s atrial chambers. It often begins as short periods of abnormal beating, which become longer or continuous over time. It may also start as other forms of arrhythmia, such as atrial flutter, that then transform into AF. AF is linked to several forms of cardiovascular disease but may occur in otherwise normal hearts.

AF has also been classified into valvular and non-valvular AF. In general, valvular AF is where the cause of AF is related to an implanted artificial heart valve or rheumatic heart disease. The proportion of patients with valvular AF has been reported to range from 4% to 30% of all patients with AF.

Atrial Fibrillation Market Key Facts

  • As per the estimates, between 2.7 million and 6.1 million people in the United States have Atrial Fibrillation. As the U.S. population ages, this number is expected to increase.

  • In 2017, Atrial Fibrillation was mentioned on 166,700+ death certificates and was the underlying cause of death in 26,000 of those deaths.

  • More than 454,000+ hospitalizations with Atrial Fibrillation as the primary diagnosis in the United States happen each year. The condition contributes to about 158,000+ deaths each year.

  • According to the study by Velecca et al., the high cost of Atrial Fibrillation is largely attributable to hospitalizations and complications such as stroke. In 2015, stroke was estimated to cost €45 billion a year in the European Union (EU).

Atrial Fibrillation Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Atrial Fibrillation market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Atrial Fibrillation market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Atrial Fibrillation Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Atrial Fibrillation Epidemiology Segmentation

  • Prevalent cases of Atrial Fibrillation

  • Diagnosed and Treatable cases of Atrial Fibrillation

  • Age-specific Prevalence of Atrial Fibrillation

  • Gender-specific Prevalence of Atrial Fibrillation

  • Type-specific Prevalent cases of Atrial Fibrillation

Atrial Fibrillation Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atrial Fibrillation market or expected to get launched during the study period. The analysis covers the Atrial Fibrillation market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Atrial Fibrillation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Atrial Fibrillation Market Will Evolve by 2032 @

Atrial Fibrillation Therapeutics Analysis

The pipeline of Atrial Fibrillation is quite robust, with several products being under evaluation in the developmental stage. There are several key players involved in the development of promising products

Some of the key companies in the Atrial Fibrillation Market include:

  • Bayer

  • Allergan

  • Anthos Therapeutics

  • Omeicos Therapeutics 

  • InCarda Therapeutics

And many others.

Atrial Fibrillation Therapies covered in the report include:

  • MAA868

  • OMT-28

  • BAY2433334 

  • InRhythm 

  • AGN-151607

And many more. 

The expected launch of emerging therapies and an increase in clinical studies are expected to create a significant impact on the market size during the forecast period (2022-2032).

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Atrial Fibrillation Competitive Intelligence Analysis

4. Atrial Fibrillation Market Overview at a Glance

5. Atrial Fibrillation Disease Background and Overview

6. Atrial Fibrillation Patient Journey

7. Atrial Fibrillation Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Atrial Fibrillation Treatment Algorithm, Current Treatment, and Medical Practices

9. Atrial Fibrillation Unmet Needs

10. Key Endpoints of Atrial Fibrillation Treatment

11. Atrial Fibrillation Marketed Products

12. Atrial Fibrillation Emerging Drugs and Latest Therapeutic Advances

13. Atrial Fibrillation Seven Major Market Analysis

14. Attribute Analysis

15. Atrial Fibrillation Market Outlook (In US, EU5, and Japan)

16. Atrial Fibrillation Access and Reimbursement Overview

17. KOL Views on the Atrial Fibrillation Market

18. Atrial Fibrillation Market Drivers

19. Atrial Fibrillation Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Cushing’s Syndrome Market

“Cushing’s Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Cushing’s Syndrome Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States